- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05791383
taVNS on the Inpatient Psychiatric Unit
February 22, 2024 updated by: Bashar Badran, Medical University of South Carolina
Managing Inpatient Neuropsychiatric Conditions Using Wearable Auricular Vagus Stimulation: The iWAVE Pilot Trial
This is a research study to find out if mental health symptoms in patients admitted to the Institute of Psychiatry are affected by a form of ear stimulation called transcutaneous auricular vagus nerve stimulation, or taVNS.
Participants will receive ear stimulation during their inpatient treatment at the Institute of Psychiatry.
Participants will be randomly assigned to either receive ear stimulation for 1 day (up to 9 treatments over the course of a single day) or 3 days (up to 3 treatments per day), and will have a 50:50 chance of being in either group (like the flip of a coin).
Each treatment will last up to 30 minutes and there will be a break of at least 30 minutes in between treatments.
The study team will ask participants to complete a group of questionnaires at the beginning and end of the study.
In addition, there are several questionnaires that will be completed daily while participants are receiving ear stimulation.
Participants in the 1 day stimulation group will also receive 2 days of follow up questionnaires after the initial day of stimulation.
The questionnaires will ask questions about mental health symptoms that subjects may or may not be experiencing, including questions about mood, anxiety, and sleep.
The ear stimulation treatments will not interfere with the care subjects are receiving from the medical team.
In order to qualify for this study, participants must be actively receiving inpatient care at the MUSC Institute of Psychiatry.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bashar W Badran, PhD
- Phone Number: 843-792-6076
- Email: badran@musc.edu
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina Institute of Psychiatry
-
Contact:
- Bashar W Badran, PhD
- Phone Number: 843-792-6076
- Email: badran@musc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Ages 18 and up
- English speaking
- Admitted to 3 North's inpatient unit in MUSC's Institute of Psychiatry (IOP)
- Have the capacity and ability to provide one's own consent and sign the informed consent document
- Primary depression diagnosis
Exclusion Criteria:
- Facial or ear pain or recent ear trauma.
- Metal implant devices in the head, heart or neck.
- History of brain surgery.
- History of myocardial infarction or arrhythmia, bradycardia.
- Acute exacerbation of a chronic respiratory disorder or acute COVID-related symptoms.
- Active GI symptoms with a history of diabetes mellitus or history of gastroparesis secondary to diabetes mellitus.
- Personal or family history of seizure or epilepsy or personal use of medications that substantially reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium).
- Personal history of head injury, concussion, or self-report of moderate to severe traumatic brain injury.
- Individuals suffering from frequent/severe headaches.
- Individuals with a reported history of psychosis or mania, or individuals who are actively manic or psychotic.
- Individuals who are catatonic or otherwise unable to participate in the informed consent process.
- Moderate to severe alcohol or substance use disorder.
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: transcutaneous auricular neurostimulation (low dose)
All taVNS procedures will be conducted using the Spark Biomedical device.
Electrodes will be placed on the left auricle and we will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes.
The low dose taVNS group will receive up to 3 treatments per day over the course of 3 days (for a total of up to 9 treatments).
|
All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device.
We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes.
taVNS sessions are considered complete after 30minutes.
Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion.
All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.
|
Experimental: transcutaneous auricular neurostimulation (high dose)
All taVNS procedures will be conducted using the Spark Biomedical device.
Electrodes will be placed on the left auricle and we will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes.
The high dose taVNS group will receive up to 9 treatments in a single day.
|
All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device.
We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes.
taVNS sessions are considered complete after 30minutes.
Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion.
All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Side Effect and Adverse Event Report
Time Frame: 4 days
|
Subjects will be monitored for adverse effects while receiving treatments.
|
4 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
General Anxiety Disorder-7 (GAD-7) Scale
Time Frame: 4 days
|
Subjects will conduct pre- and post- anxiety assessments to understand if stimulation improves neuropsychiatric condition.
Higher GAD-7 scores indicate higher anxiety symptoms.
|
4 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2022
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
January 4, 2023
First Submitted That Met QC Criteria
March 28, 2023
First Posted (Actual)
March 30, 2023
Study Record Updates
Last Update Posted (Actual)
February 23, 2024
Last Update Submitted That Met QC Criteria
February 22, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00120876
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression, Anxiety
-
University Hospital, Strasbourg, FranceCompletedAnxiety Depression DisorderFrance
-
ViomeRecruitingDepression | Anxiety Disorders | Anxiety | Mental Health Disorder | Anxiety Depression | Anxiety State | Mental Health | Depression, Anxiety | Mental Health IssueUnited States
-
3-C Institute for Social DevelopmentUniversity of Miami; Stony Brook UniversityCompletedDepression | Anxiety | Depression, Anxiety | Depression in AdolescenceUnited States
-
University Hospital, Strasbourg, FranceRecruitingDepression Anxiety DisorderFrance
-
UCLH/UCL Joint Research OfficeMedical Research Council; Camden and Islington NHS Trust; Central and North West...RecruitingAnxiety Disorders | Anxiety | Anxiety Depression | CBT | Anxiety Disorders and Symptoms | Anxiety Generalized | Generalised Anxiety Disorder | Anxiety Disorder; Mixed With Depression (Mild) | Anxiety Disorder GeneralizedUnited Kingdom
-
University of Southern CaliforniaCompletedAnxiety | Depression, Anxiety | Depression Mild | Attention Concentration DifficultyUnited States
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH); California Institute of TechnologyRecruitingDepression | Anxiety Disorders | Fear | Depression, Anxiety | Anxiety and Fear | Anxious DepressionUnited States
-
San Diego State UniversityKaiser Permanente; OCHIN, Inc.Not yet recruiting
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Not yet recruitingDepression | Anxiety Disorders | Anxiety | Depression, Anxiety
-
Henan Provincial People's HospitalNot yet recruiting
Clinical Trials on transcutaneous auricular neurostimulation
-
The University of Texas Medical Branch, GalvestonNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingUnderstanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic PainAnalgesia | Opioid WithdrawalUnited States
-
Medical University of South CarolinaRecruitingHypermobile Ehlers-Danlos Syndrome | Ehlers-Danlos Syndrome | Hypermobile Spectrum DisorderUnited States
-
University of Texas Southwestern Medical CenterNot yet recruitingTBI (Traumatic Brain Injury)United States
-
Spark Biomedical, Inc.CompletedOpioid-use Disorder | Opioid WithdrawalUnited States
-
Medical College of WisconsinCompletedPain, PostoperativeUnited States
-
Spark Biomedical, Inc.Medical University of South CarolinaCompleted
-
University of Texas Southwestern Medical CenterNot yet recruitingPain, Postoperative | Opioid Use | Lumbar Spine InjuryUnited States
-
Centro Universitario de TonaláUniversity of Guadalajara; Diabetes sin Complicaciones S.A de C.V, MexicoTerminatedDiabetic Neuropathy PeripheralMexico
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedFunctional Gastrointestinal DisordersUnited States
-
Medical University of ViennaRecruitingVagus Nerve Diseases | Post-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID ConditionAustria